» Articles » PMID: 15765806

Prevalence and Pattern of Neuropsychological Impairment in Human Immunodeficiency Virus-infected/acquired Immunodeficiency Syndrome (HIV/AIDS) Patients Across Pre- and Post-highly Active Antiretroviral Therapy Eras: a Combined Study of Two Cohorts

Overview
Journal J Neurovirol
Publisher Springer
Specialties Microbiology
Neurology
Date 2005 Mar 16
PMID 15765806
Citations 195
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of this study was to assess the prevalence and pattern of neuropsychological impairment in cohorts of human immunodeficiency virus (HIV)-infected individuals across pre- and post-HAART (highly active antiretroviral therapy) eras. Two cohorts of HIV-infected individuals attending tertiary referral hospital outpatient clinics were studied. The cohorts represented two eras of antiretroviral medication: monotherapy (n = 51) and HAART (n = 90). Each was compared in nine neuropsychological domains in regard to the prevalence as well as pattern of neuropsychological impairment. Because the authors intended to characterize the prevalence and pattern of neuropsychological deficits in nondemented advanced HIV-infected individuals, patients with a current diagnosis of acquired immunodeficiency syndrome (AIDS) dementia complex were not included. The prevalence of impairment was not significantly different across pre-HAART and HAART eras using a standard criterion to define impairment: -2 SD in two neuropsychological measures (41.1%/38.8%). Prevalence of deficits was not significantly reduced in patients with undetectable plasma viral load. The pattern of neuropsychological impairment was different across pre-HAART and HAART eras, with an improvement in attention, verbal fluency, visuoconstruction deficits, but a deterioration in learning efficiency and complex attention. This change remained even in patients with an undetectable plasma viral load, although the severity was partially diminished. Neuropsychological deficits remain common in the HAART era, essentially uninfluenced by HAART. The finding that some neuropsychological functions are improving while other are deteriorating indicates that these deficits do not reflect "burnt out" damage but rather that there is an active intracerebral process occurring, the nature of which is still to be determined.

Citing Articles

Assessing cognitive impairment in HIV-infected: a comparative study of international HIV Dementia Scale, HIV Dementia Scale Italian version and Montreal cognitive assessment in clinical practice.

Belfiori M, Salis F, Podda C, Stanisci L, Puxeddu B, Ortu F J Neurovirol. 2025; .

PMID: 40019698 DOI: 10.1007/s13365-025-01248-9.


Hub disruption in HIV disease and cocaine use: A connectomics analysis of brain function.

Al-Khalil K, Bell R, Towe S, Cohen J, Gadde S, Mu J Drug Alcohol Depend. 2024; 263:112416.

PMID: 39197360 PMC: 11620762. DOI: 10.1016/j.drugalcdep.2024.112416.


Cannabinoid receptor 1 positive allosteric modulator ZCZ011 shows differential effects on behavior and the endocannabinoid system in HIV-1 Tat transgenic female and male mice.

Yadav-Samudrala B, Dodson H, Ramineni S, Kim E, Poklis J, Lu D PLoS One. 2024; 19(6):e0305868.

PMID: 38913661 PMC: 11195999. DOI: 10.1371/journal.pone.0305868.


CD4 nadir and neurocognitive trajectories in people living with HIV.

Garabet R, Dampier W, Tillman S, Malone K, Szep Z, Althoff A J Neurovirol. 2024; 30(4):423-433.

PMID: 38856821 PMC: 11512832. DOI: 10.1007/s13365-024-01217-8.


HIV and COVID-19: two pandemics with significant (but different) central nervous system complications.

Magaki S, Zhang T, Han K, Hilda M, Yong W, Achim C Free Neuropathol. 2024; 5.

PMID: 38469363 PMC: 10925920. DOI: 10.17879/freeneuropathology-2024-5343.


References
1.
Sacktor N, Bacellar H, Hoover D, Selnes O, Miller E, Dal Pan G . Psychomotor slowing in HIV infection: a predictor of dementia, AIDS and death. J Neurovirol. 1996; 2(6):404-10. DOI: 10.3109/13550289609146906. View

2.
Neuenburg J, Brodt H, Herndier B, Bickel M, Bacchetti P, Price R . HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002; 31(2):171-7. DOI: 10.1097/00126334-200210010-00007. View

3.
Grunseit A, Perdices M, Dunbar N, Cooper D . Neuropsychological function in asymptomatic HIV-1 infection: methodological issues. J Clin Exp Neuropsychol. 1994; 16(6):898-910. DOI: 10.1080/01688639408402701. View

4.
Cunningham P, Smith D, Satchell C, Cooper D, Brew B . Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS. 2000; 14(13):1949-54. DOI: 10.1097/00002030-200009080-00010. View

5.
Dore G, McDonald A, Li Y, Kaldor J, Brew B . Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 2003; 17(10):1539-45. DOI: 10.1097/00002030-200307040-00015. View